Skip to content
Pfizer to buy maker of respiratory virus drugs

Pfizer Inc. has agreed to buy a private drugmaker developing drugs for a potentially deadly respiratory virus, a deal the big drugmaker aims to bolster its efforts in the fight against infectious diseases.

Pfizer said Thursday it had reached an agreement to buy ReViral Ltd. and its experimental drug, sisunatovir, for up to $525 million if milestones are met.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.